Chronic rhinosinusitis with nasal polyps impact in severe asthma patients: Evidences from the Severe Asthma Network Italy (SANI) registry.
Administration, Oral
Adrenal Cortex Hormones
/ administration & dosage
Adult
Aged
Asthma
/ drug therapy
Chronic Disease
Comorbidity
Databases, Factual
Disease Progression
Female
Humans
Internet
Italy
/ epidemiology
Male
Middle Aged
Nasal Polyps
Nitric Oxide
/ metabolism
Prevalence
Registries
Rhinitis
/ epidemiology
Severity of Illness Index
Sinusitis
/ epidemiology
Comorbidities
Nasal polyps
Oral corticosteroids
Severe asthma
Journal
Respiratory medicine
ISSN: 1532-3064
Titre abrégé: Respir Med
Pays: England
ID NLM: 8908438
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
received:
22
01
2020
revised:
24
03
2020
accepted:
25
03
2020
pubmed:
7
4
2020
medline:
10
10
2020
entrez:
7
4
2020
Statut:
ppublish
Résumé
The clinical and laboratory features of patients enrolled in the Severe Asthma Network in Italy (SANI) registry, a web-based observatory collecting demographic, clinical, functional and inflammatory data of patients with severe asthma were evaluated, with a special emphasis to chronic rhinosinusitis with nasal polyposis (CRSwNP). For each eligible patients the following information has been collected: demographic data, clinical features, asthma control in the previous month according to the GINA (Global INitiative for Asthma) Guidelines and standardized questionnaires, concomitant regular and on demand treatments and inflammatory markers. 695 patients with severe asthma enrolled in 66 SANI centers were analyzed. The prevalence of chronic rhinosinusitis with nasal polyposis was 40.6%. Atopic dermatitis and bronchiectasis was significantly more frequent in patients with CRSwNP than in subjects without nasal polyposis; similarly, FeNO values are significantly higher in subject with CRSwNP than in patients without nasal polyposis. Finally, patients with CRSwNP had a significantly higher number of asthma exacerbations per year, more days on oral corticosteroids and were more likely to be OCS long term users. OCS sparing is needed in patients with severe asthma, mainly in subjects with CRSwNP, adopting adequate strategies such as a better adherence to the treatment with inhaled therapy according to the GINA recommendations, the use of biologic agents and a multidisciplinary approach of the patient.
Sections du résumé
BACKGROUND
The clinical and laboratory features of patients enrolled in the Severe Asthma Network in Italy (SANI) registry, a web-based observatory collecting demographic, clinical, functional and inflammatory data of patients with severe asthma were evaluated, with a special emphasis to chronic rhinosinusitis with nasal polyposis (CRSwNP).
METHODS
For each eligible patients the following information has been collected: demographic data, clinical features, asthma control in the previous month according to the GINA (Global INitiative for Asthma) Guidelines and standardized questionnaires, concomitant regular and on demand treatments and inflammatory markers.
RESULTS
695 patients with severe asthma enrolled in 66 SANI centers were analyzed. The prevalence of chronic rhinosinusitis with nasal polyposis was 40.6%. Atopic dermatitis and bronchiectasis was significantly more frequent in patients with CRSwNP than in subjects without nasal polyposis; similarly, FeNO values are significantly higher in subject with CRSwNP than in patients without nasal polyposis. Finally, patients with CRSwNP had a significantly higher number of asthma exacerbations per year, more days on oral corticosteroids and were more likely to be OCS long term users.
CONCLUSION
OCS sparing is needed in patients with severe asthma, mainly in subjects with CRSwNP, adopting adequate strategies such as a better adherence to the treatment with inhaled therapy according to the GINA recommendations, the use of biologic agents and a multidisciplinary approach of the patient.
Identifiants
pubmed: 32250875
pii: S0954-6111(20)30087-1
doi: 10.1016/j.rmed.2020.105947
pii:
doi:
Substances chimiques
Adrenal Cortex Hormones
0
Nitric Oxide
31C4KY9ESH
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
105947Investigateurs
M Bonavia
(M)
P Caiaffa
(P)
C Calabrese
(C)
G Camiciottoli
(G)
C Caruso
(C)
S Centanni
(S)
M E Conte
(ME)
A G Corsico
(AG)
L Cosmi
(L)
M T Costantino
(MT)
N Crimi
(N)
S D'Alò
(S)
M D'Amato
(M)
S Del Giacco
(S)
E Favero
(E)
A Farsi
(A)
B P M Foschino
(BPM)
G Guarnieri
(G)
G Guida
(G)
M Latorre
(M)
C Lombardi
(C)
L Macchia
(L)
F Menzella
(F)
M Milanese
(M)
P Montuschi
(P)
E Nucera
(E)
R Parente
(R)
G Passalacqua
(G)
V Patella
(V)
G Pelaia
(G)
L Pini
(L)
F L M Ricciardolo
(FLM)
L Ricciardi
(L)
L Richeldi
(L)
E Ridolo
(E)
G Rolla
(G)
P Santus
(P)
N Scichilone
(N)
P Solidoro
(P)
G Spadaro
(G)
A Spanevello
(A)
A Vianello
(A)
M R Yacoub
(MR)
M C Zappa
(MC)
Informations de copyright
Copyright © 2020 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.